Amgen (AMGN) Net Cash Flow (2009 - 2026)
Amgen (AMGN) posted quarterly Net Cash Flow of $2.9 billion for Q1 2026, up 191.97% year-over-year from $996.3 million in Q1 2025, and up 1020.57% quarter-over-quarter from -$316.0 million in Q4 2025.
Amgen (AMGN) Net Cash Flow (2009 - 2026) Analysis & Trends
Amgen's Net Cash Flow history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.
- In Q1 2026, Net Cash Flow rose 191.97% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $3.2 billion (up 459.47% YoY), while the FY2025 annual figure was -$2.8 billion, down 376.38% from the prior year.
- Net Cash Flow for Q1 2026 stood at $2.9 billion, up from -$316.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $23.9 billion in Q1 2023, with the low at -$23.8 billion in Q4 2023.
- The 5-year median for Net Cash Flow is -$316.0 million (2025), against an average of $238.2 million.
- Peak annual rise in Net Cash Flow reached 1737.99% in 2023, while the deepest fall reached 1170.53% in 2023.
- Amgen's Net Cash Flow stood at -$1.9 billion in 2022, then slumped by 1170.53% to -$23.8 billion in 2023, then jumped by 112.45% to $3.0 billion in 2024, then slumped by 110.67% to -$316.0 million in 2025, then jumped by 1020.57% to $2.9 billion in 2026.
- Business Quant data shows AMGN's Net Cash Flow at $2.9 billion in Q1 2026, -$316.0 million in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Bn |
| Jun 30, 2026 | 1.95 Bn |
| Mar 31, 2026 | 2.91 Bn |
| Mar 31, 2026 | 2.91 Bn |
| Dec 31, 2025 | -316.00 Mn |
| Dec 31, 2025 | -316.00 Mn |
| Sep 30, 2025 | 1.42 Bn |
| Sep 30, 2025 | 1.42 Bn |
| Jun 30, 2025 | -782.00 Mn |
| Jun 30, 2025 | -782.00 Mn |
| Mar 31, 2025 | -3.16 Bn |
| Mar 31, 2025 | -3.16 Bn |
| Dec 31, 2024 | 2.96 Bn |
| Dec 31, 2024 | 2.96 Bn |
| Sep 30, 2024 | -290.00 Mn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | -407.00 Mn |
| Jun 30, 2024 | -407.00 Mn |
| Mar 31, 2024 | -1.24 Bn |
| Mar 31, 2024 | -1.24 Bn |